Contact Information
1211 21st Ave South215 MAB
Nashville, TN 37232-1371
United States of American
615-936-2630 (tel)
615-936-1308 (fax)
Mo Sika Ph.D.
Department: Medicine
Biography
Research Associate Professor, Administrative Director of Nephrology Clinical Trials Center
Since joining the Nephrology Clinical Trials Center at Vanderbilt in 1997, I have participated in more than 60 clinical trials (Federal, Pharmaceutical, and Investigator-initiated) related to progression of chronic kidney
disease, dialysis, and kidney transplantation under different Principal Investigators (Lewis, Schulman, Golper,Helderman, Langone, Schaefer, and Dwyer) . I have also served as a projector coordinator for 2 trials: Treatment of Diabetic Nephropathy (NIH 5R01 DK 63091-02, PI: Lewis, Julia, MD) and Development of Ferric
Citrate as a phosphate Binder (Keryx Biopharmaceuticals, Study Chair: Lewis, Julia, MD) where our center was the Clinical Coordinating Center (CCC) as well as a performing site (PI: Schulman, Gerald, MD). The first
trial (Treatment of Diabetic Nephropathy) involved 3 sites (Vanderbilt, Duke, and Rush) where I also served as a monitor to ensure the quality of the data submitted to the CCC. The second trial (Ferric Citrate) was a large multinational study involving 60 sites where in addition to answering protocol-related questions I supervised receiving, reviewing, and submitting serious adverse events reports to the medical monitors.
Featured Publications
1. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61(5): 759-66
Citation ⋅ 23369827 (PubMed)2. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Group (2012) Nephron Clin Pract 121(1-2): c25-9
Citation ⋅ 23075669 (PubMed)3. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2013) Hemodial Int 17(1): 67-74
Citation ⋅ 22702490 (PubMed)Publications
1. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013) Am J Kidney Dis 61(5): 759-66
Citation ⋅ 23369827 (PubMed)2. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients.
Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Group (2012) Nephron Clin Pract 121(1-2): c25-9
Citation ⋅ 23075669 (PubMed)3. Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis.
Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2013) Hemodial Int 17(1): 67-74
Citation ⋅ 22702490 (PubMed)4. Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort.
Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, Pogue V, Sika M, Wang X, AASK Collaborative Research Group (2010) Am J Kidney Dis 56(5): 896-906
Citation ⋅ 20801567 (PubMed) PMC4517588 (PubMed Central)5. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease.
Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA, African American Study of Kidney Disease and Hypertension Collaborative Research Group (2009) Hypertension 53(1): 20-7
Citation ⋅ 19047584 (PubMed)6. Predictors of participant adherence and retention in the African American Study of Kidney Disease and Hypertension.
Brooks D, Charleston J, Dowie D, Gabriel A, Hall YB, Hiremath L, Lightfoot T, Sika M, Smith WC, Wang X (2008) Nephrol Nurs J 35(2): 133-42
Citation ⋅ 18472682 (PubMed)7. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J (2007) Am J Kidney Dis 50(6): 946-51
Citation ⋅ 18037095 (PubMed)8. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease.
Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M, Feldman H, Gassman J, Lea J, Kopple J, Sika M, Toto R, Greene T (2006) J Am Soc Nephrol 17(10): 2900-9
Citation ⋅ 16988064 (PubMed)9. Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M, African American Study of Kidney Disease and Hypertension Trial Study Group (2006) Am J Kidney Dis 47(6): 956-64
Citation ⋅ 16731290 (PubMed)10. WAGR syndrome: a clinical review of 54 cases.
Fischbach BV, Trout KL, Lewis J, Luis CA, Sika M (2005) Pediatrics 116(4): 984-8
Citation ⋅ 16199712 (PubMed)11. Blood pressure control, drug therapy, and kidney disease.
Contreras G, Greene T, Agodoa LY, Cheek D, Junco G, Dowie D, Lash J, Lipkowitz M, Miller ER, Ojo A, Sika M, Wilkening B, Toto RD, African American Study of Kidney Disease and Hypertension Study Group Investigators (2005) Hypertension 46(1): 44-50
Citation ⋅ 15897360 (PubMed)